Sarah Rose Lowrey (@SarahLowrey)

Remdesivir, the only approved treatment for hospitalized patients, cost an estimated $5 (pdf) to produce and was sold to the U.S. government for $2,340 a course—a price now pegged too high for many patients. Monoclonal antibody courses, used to treat mild or asymptomatic COVID-19 cases, cost around $2,100 per course. The cost of production for the monoclonals is not clear. https://www.theepochtimes.com/mkt_breakingnews/us-set-to-pay-712-per-patient-for-mercks-covid-19-pill_4050864.html?utm_source=newsnoe&utm_medium=email&utm_campaign=breaking-2021-10-16-3&mktids=13aafc03c66a108c0f984ef613c421ff&est=mrOxkqAdwwqErMhx6hGzPzcM28l%2BzlGGO40tIetyOba7WOzpKT0v6C/GlkE=